Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06653400 · ClinicalTrials.gov registry record · Phase 1

Combined Ketorolac and Lidocaine Paracervical Block for Office Hysteroscopy

A Phase 1 study of Analgesia and Abnormal Uterine Bleeding, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT06653400 is a Phase 1 study of Analgesia and Abnormal Uterine Bleeding that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 60 participants, below the 90-participant average among 19 other Analgesia trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06653400, a Phase 1 study of Analgesia and Abnormal Uterine Bleeding, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

A randomized double-blind placebo controlled trial comparing the effect of a combined ketorolac and lidocaine paracervical block with a standard lidocaine paracervical block on procedure related pain with office hysteroscopies.

Interventions

  • DRUG Lidocaine
  • PROCEDURE paracervical block
  • DRUG ketorolac

Study Locations (1)

New York

  • Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-02-27
Est. Completion 2026-09-01
Phase Phase 1

What the Registry Record Tells You About NCT06653400

The ClinicalTrials.gov registry entry for NCT06653400 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 19 other Analgesia trials with a reported enrollment target (33% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Analgesia appearing as the primary indexed condition, and to 3 interventions - of which Lidocaine is the first listed.

NCT06653400 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06653400 about?

NCT06653400 is a clinical study titled "Combined Ketorolac and Lidocaine Paracervical Block for Office Hysteroscopy". A randomized double-blind placebo controlled trial comparing the effect of a combined ketorolac and lidocaine paracervical block with a standard lidocaine paracervical block on procedure related pain with office hysteroscopies.

What is the current status of trial NCT06653400?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-02-27. Estimated completion is 2026-09-01.

What conditions does trial NCT06653400 study?

This clinical trial studies the following conditions: Analgesia, Abnormal Uterine Bleeding, Paracervical Block.

What interventions are being tested in trial NCT06653400?

The interventions under investigation include: Lidocaine (DRUG), paracervical block (PROCEDURE), ketorolac (DRUG).

Who is sponsoring clinical trial NCT06653400?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06653400 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Analgesia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.